Regulation of HGF expression by δEGFR-mediated c-Met activation in glioblastoma cells

Jeannine Garnett, Vaibhav Chumbalkar, Brian Vaillant, Anupama E. Gururaj, Kristen S. Hill, Khatri Latha, Jun Yao, Waldemar Priebe, Howard Colman, Lisa Elferink, Oliver Bogler

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The hepatocyte growth factor receptor (c-Met) and a constitutively active mutant of the epidermal growth factor receptor (δEGFR/EGFRvIII) are frequently overexpressed in glioblastoma (GBM) and promote tumorigenesis. The mechanisms underlying elevated hepatocyte growth factor (HGF) production in GBM are not understood. We found higher, coordinated mRNA expression levels of HGF and c-Met in mesenchymal (Mes) GBMs, a subtype associated with poor treatment response and shorter overall survival. In an HGF/c-Met-dependent GBM cell line, HGF expression declined upon silencing of c-Met using RNAi or by inhibiting its activity with SU11274. Silencing c-Met decreased anchorage-independent colony formation and increased the survival of mice bearing intracranial GBM xenografts. Consistent with these findings, c-Met activation by ΔEGFR also elevated HGF expression, and the inhibition of ΔEGFR with AG1478 reduced HGF levels. Interestingly, c-Met expression was required for ΔEGFR-mediated HGF production, anchorage-independent growth, and in vivo tumorigenicity, suggesting that these pathways are coupled. Using an unbiased mass spectrometry-based screen, we show that signal transducer and activator of transcription 3 (STAT3) Y705 is a downstream target of c-Met signaling. Suppression of STAT3 phosphorylation with WP1193 reduced HGF expression in ΔEGFR-expressing GBM cells, whereas constitutively active STAT3 partially rescued HGF expression and colony formation in c-Met knockdown cells expressing ΔEGFR. These results suggest that the c-Met/HGF signaling axis is enhanced by ΔEGFR through increased STAT3-dependent HGF expression and that targeting c-Met in Mes GBMs may be an important strategy for therapy.

Original languageEnglish (US)
Pages (from-to)73-84
Number of pages12
JournalNeoplasia (United States)
Volume15
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Hepatocyte Growth Factor
Glioblastoma
STAT3 Transcription Factor
Proto-Oncogene Proteins c-met
RNA Interference
Epidermal Growth Factor Receptor
Heterografts
Mass Spectrometry
Carcinogenesis
Phosphorylation

ASJC Scopus subject areas

  • Cancer Research

Cite this

Garnett, J., Chumbalkar, V., Vaillant, B., Gururaj, A. E., Hill, K. S., Latha, K., ... Bogler, O. (2013). Regulation of HGF expression by δEGFR-mediated c-Met activation in glioblastoma cells. Neoplasia (United States), 15(1), 73-84. https://doi.org/10.1593/neo.121536

Regulation of HGF expression by δEGFR-mediated c-Met activation in glioblastoma cells. / Garnett, Jeannine; Chumbalkar, Vaibhav; Vaillant, Brian; Gururaj, Anupama E.; Hill, Kristen S.; Latha, Khatri; Yao, Jun; Priebe, Waldemar; Colman, Howard; Elferink, Lisa; Bogler, Oliver.

In: Neoplasia (United States), Vol. 15, No. 1, 01.2013, p. 73-84.

Research output: Contribution to journalArticle

Garnett, J, Chumbalkar, V, Vaillant, B, Gururaj, AE, Hill, KS, Latha, K, Yao, J, Priebe, W, Colman, H, Elferink, L & Bogler, O 2013, 'Regulation of HGF expression by δEGFR-mediated c-Met activation in glioblastoma cells', Neoplasia (United States), vol. 15, no. 1, pp. 73-84. https://doi.org/10.1593/neo.121536
Garnett J, Chumbalkar V, Vaillant B, Gururaj AE, Hill KS, Latha K et al. Regulation of HGF expression by δEGFR-mediated c-Met activation in glioblastoma cells. Neoplasia (United States). 2013 Jan;15(1):73-84. https://doi.org/10.1593/neo.121536
Garnett, Jeannine ; Chumbalkar, Vaibhav ; Vaillant, Brian ; Gururaj, Anupama E. ; Hill, Kristen S. ; Latha, Khatri ; Yao, Jun ; Priebe, Waldemar ; Colman, Howard ; Elferink, Lisa ; Bogler, Oliver. / Regulation of HGF expression by δEGFR-mediated c-Met activation in glioblastoma cells. In: Neoplasia (United States). 2013 ; Vol. 15, No. 1. pp. 73-84.
@article{a93bddda64884107b254979693932638,
title = "Regulation of HGF expression by δEGFR-mediated c-Met activation in glioblastoma cells",
abstract = "The hepatocyte growth factor receptor (c-Met) and a constitutively active mutant of the epidermal growth factor receptor (δEGFR/EGFRvIII) are frequently overexpressed in glioblastoma (GBM) and promote tumorigenesis. The mechanisms underlying elevated hepatocyte growth factor (HGF) production in GBM are not understood. We found higher, coordinated mRNA expression levels of HGF and c-Met in mesenchymal (Mes) GBMs, a subtype associated with poor treatment response and shorter overall survival. In an HGF/c-Met-dependent GBM cell line, HGF expression declined upon silencing of c-Met using RNAi or by inhibiting its activity with SU11274. Silencing c-Met decreased anchorage-independent colony formation and increased the survival of mice bearing intracranial GBM xenografts. Consistent with these findings, c-Met activation by ΔEGFR also elevated HGF expression, and the inhibition of ΔEGFR with AG1478 reduced HGF levels. Interestingly, c-Met expression was required for ΔEGFR-mediated HGF production, anchorage-independent growth, and in vivo tumorigenicity, suggesting that these pathways are coupled. Using an unbiased mass spectrometry-based screen, we show that signal transducer and activator of transcription 3 (STAT3) Y705 is a downstream target of c-Met signaling. Suppression of STAT3 phosphorylation with WP1193 reduced HGF expression in ΔEGFR-expressing GBM cells, whereas constitutively active STAT3 partially rescued HGF expression and colony formation in c-Met knockdown cells expressing ΔEGFR. These results suggest that the c-Met/HGF signaling axis is enhanced by ΔEGFR through increased STAT3-dependent HGF expression and that targeting c-Met in Mes GBMs may be an important strategy for therapy.",
author = "Jeannine Garnett and Vaibhav Chumbalkar and Brian Vaillant and Gururaj, {Anupama E.} and Hill, {Kristen S.} and Khatri Latha and Jun Yao and Waldemar Priebe and Howard Colman and Lisa Elferink and Oliver Bogler",
year = "2013",
month = "1",
doi = "10.1593/neo.121536",
language = "English (US)",
volume = "15",
pages = "73--84",
journal = "Neoplasia (United States)",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Regulation of HGF expression by δEGFR-mediated c-Met activation in glioblastoma cells

AU - Garnett, Jeannine

AU - Chumbalkar, Vaibhav

AU - Vaillant, Brian

AU - Gururaj, Anupama E.

AU - Hill, Kristen S.

AU - Latha, Khatri

AU - Yao, Jun

AU - Priebe, Waldemar

AU - Colman, Howard

AU - Elferink, Lisa

AU - Bogler, Oliver

PY - 2013/1

Y1 - 2013/1

N2 - The hepatocyte growth factor receptor (c-Met) and a constitutively active mutant of the epidermal growth factor receptor (δEGFR/EGFRvIII) are frequently overexpressed in glioblastoma (GBM) and promote tumorigenesis. The mechanisms underlying elevated hepatocyte growth factor (HGF) production in GBM are not understood. We found higher, coordinated mRNA expression levels of HGF and c-Met in mesenchymal (Mes) GBMs, a subtype associated with poor treatment response and shorter overall survival. In an HGF/c-Met-dependent GBM cell line, HGF expression declined upon silencing of c-Met using RNAi or by inhibiting its activity with SU11274. Silencing c-Met decreased anchorage-independent colony formation and increased the survival of mice bearing intracranial GBM xenografts. Consistent with these findings, c-Met activation by ΔEGFR also elevated HGF expression, and the inhibition of ΔEGFR with AG1478 reduced HGF levels. Interestingly, c-Met expression was required for ΔEGFR-mediated HGF production, anchorage-independent growth, and in vivo tumorigenicity, suggesting that these pathways are coupled. Using an unbiased mass spectrometry-based screen, we show that signal transducer and activator of transcription 3 (STAT3) Y705 is a downstream target of c-Met signaling. Suppression of STAT3 phosphorylation with WP1193 reduced HGF expression in ΔEGFR-expressing GBM cells, whereas constitutively active STAT3 partially rescued HGF expression and colony formation in c-Met knockdown cells expressing ΔEGFR. These results suggest that the c-Met/HGF signaling axis is enhanced by ΔEGFR through increased STAT3-dependent HGF expression and that targeting c-Met in Mes GBMs may be an important strategy for therapy.

AB - The hepatocyte growth factor receptor (c-Met) and a constitutively active mutant of the epidermal growth factor receptor (δEGFR/EGFRvIII) are frequently overexpressed in glioblastoma (GBM) and promote tumorigenesis. The mechanisms underlying elevated hepatocyte growth factor (HGF) production in GBM are not understood. We found higher, coordinated mRNA expression levels of HGF and c-Met in mesenchymal (Mes) GBMs, a subtype associated with poor treatment response and shorter overall survival. In an HGF/c-Met-dependent GBM cell line, HGF expression declined upon silencing of c-Met using RNAi or by inhibiting its activity with SU11274. Silencing c-Met decreased anchorage-independent colony formation and increased the survival of mice bearing intracranial GBM xenografts. Consistent with these findings, c-Met activation by ΔEGFR also elevated HGF expression, and the inhibition of ΔEGFR with AG1478 reduced HGF levels. Interestingly, c-Met expression was required for ΔEGFR-mediated HGF production, anchorage-independent growth, and in vivo tumorigenicity, suggesting that these pathways are coupled. Using an unbiased mass spectrometry-based screen, we show that signal transducer and activator of transcription 3 (STAT3) Y705 is a downstream target of c-Met signaling. Suppression of STAT3 phosphorylation with WP1193 reduced HGF expression in ΔEGFR-expressing GBM cells, whereas constitutively active STAT3 partially rescued HGF expression and colony formation in c-Met knockdown cells expressing ΔEGFR. These results suggest that the c-Met/HGF signaling axis is enhanced by ΔEGFR through increased STAT3-dependent HGF expression and that targeting c-Met in Mes GBMs may be an important strategy for therapy.

UR - http://www.scopus.com/inward/record.url?scp=84873030799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873030799&partnerID=8YFLogxK

U2 - 10.1593/neo.121536

DO - 10.1593/neo.121536

M3 - Article

VL - 15

SP - 73

EP - 84

JO - Neoplasia (United States)

JF - Neoplasia (United States)

SN - 1522-8002

IS - 1

ER -